Skip to main content

Call for Abstracts

26th Annual Meeting and Education Day of the Society for Neuro-Oncology
November 18 - 21, 2021

The General Abstract acceptance emails were sent on 8/6/21

Important Information
  • Embargo Details:
    • The embargo for abstracts published in the 2021 abstract supplement to SNO official journal Neuro-Oncology will lift on Friday, November 12, 2021.
    • These abstracts will be made available at:
  • Presentation Recording Onsite:
    • SNO will record all "live" slide presentations (with accompanying audio and video) during the meeting.
    • Select presentations will be featured on the SNO Education Site and will be made available for online viewing.
  • Electronic Poster Presentations:
    • Files will be captured electronically (in PDF) prior to the meeting and available on the mobile meeting app, website and onsite.
  • Presenters will be given full credit for their presentations. For the purpose of Neuro-Oncology, Neuro-Oncology Practice, and other scholarly journals, presentation in either of these forums is not considered "prior publication".
  • General Abstract Deadline was Monday, May 24, 2021, 11:59pm EDT
  • Late Breaking Abstract Deadline: Friday, September 3, 2021, 11:59pm EST.
    • Abstracts submitted to this category that do not fit the description criteria, will be withdrawn. For information and special guidelines on Late-Breaking Abstracts, click here.
  • *Please use the web browser Google Chrome when submitting an abstract.
Abstract Guidelines
  • Abstract Title:
    • Should be sentence case (i.e., only the first letter of the title should be capitalized)
    • Should be plain text (No html)
    • Word Limit: 75 words/ 200 characters
  • Abstract Body:
    • Word Limit: 300 words
    • Figures and tables are not allowed
    • Should be in a single paragraph
    • If subheaders are used, they should be within that single paragraph in all-caps, not bolded (e.g., METHODS:)
    • If you use the greater than/equal to symbol, you MUST put a space before entering the number.
    • Abstracts should be data-driven and must include this information in the body of the abstract.
    • Please be sure to carefully check your abstract for content errors, spelling, names, etc. before submitting. SNO neither proofreads for nor corrects spelling, typographical, grammatical, or scientific errors.
  • Authors:
    • There can only be 1 presenting author per submission
    • There is a maximum of 50 authors per abstract submission
    • Only the presenting author is required to submit a Conflict of Interest Disclosure.
    • Enter the names of authors in the order in which you wish them to appear in the printed text.
    • Presenting Authors will need to complete new Presenting Author Task.
  • For information and special guidelines on Late-Breaking Abstracts, click here.

Please note the following information will be requested of your abstract:

Submission Type:
  • Adult
  • Pediatric
  • Adult & Pediatric
  • Late Breaking (for more info & guidelines click here)
Abstract Tumor Type:
  • CNS Metastases
  • Nerve Sheath Tumors
  • Spinal Tumors
  • Glial Tumors
  • Embryonal Tumors (ATRT, PNET, Medullo)
  • Ependymal Tumors
  • Extra-axial (meningioma, hemangiopericytoma, pituitary)
  • Rare tumors (lymphoma, GCT, others)
  • General neuro-oncology
  • Other
Abstract Categories:
  • Clinical trials: Immunologic
  • Clinical trials: Non-immunologic
  • Randomized Trials in Development
  • Outcome measures and neuro-cognitive outcomes
  • QoL and palliative care
  • Innovations in patient care
  • Neurological complications of cancer
  • Neuro-imaging
  • Epidemiology & biostatistics
  • Radiobiology
  • Clinical radiotherapy
  • Surgical Therapies
  • Cell biology (cell cycle regulation, DNA repair/modulation)
  • Cell signaling and signaling pathways
  • Cancer stem cell
  • Tumor Microenvironment /angiogenesis / metabolism/ invasion/
  • Immunology
  • Drug discovery, drug resistance
  • Tumor models
  • Preclinical Experimental Therapeutics
  • (Epi)genetics and computational omics
  • Molecular pathology & classification
  • Biomarkers

Please contact Tara Mammoser at